The roles of lncRNA functions and regulatory mechanisms in the diagnosis and treatment of hepatocellular carcinoma

Hong, Yuling; Zhang, Yunxing; Zhao, Haibo; Chen, Hailing; Yu, Qingqing; Cui, Hongxia

doi:10.3389/fcell.2022.1051306

Cited by 5 publications

(4 citation statements)

References 199 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite their lack of protein-coding potential, lncRNAs intricately coordinate various cellular processes, and their dysregulation is increasingly implicated in cancer initiation and progression. 227 In the realm of cancer resistance, the regulatory influence of lncRNAs takes a critical role ( Table 1 ). These transcripts, characterized by extensive nucleotide sequences, engage in diverse molecular mechanisms that govern gene expression, 228 cellular pathways, 229 and, notably, the adaptive responses of cancer cells in the face of therapeutic challenges.…”

Section: Non-coding Rnas Regulationmentioning

confidence: 99%

Hallmarks of cancer resistance

Tufail,

Hu,

Liang

et al. 2024

iScience

View full text Add to dashboard Cite

Section: Non-coding Rnas Regulationmentioning

confidence: 99%

Hallmarks of cancer resistance

Tufail,

Hu,

Liang

et al. 2024

iScience

View full text Add to dashboard Cite

“…Previous studies have shown that lncRNAs may be involved in the regulation of the DDR processes [ 8 – 10 ]. Moreover, DDR-related lncRNAs may be involved in HCC progression [ 11 ]. LncRNA PRLH1 can bind to the DNA repair protein RNF169, and promote the recruitment and retention of RNF169, thereby promoting homologous recombination repair and increasing proliferation in HCC cells [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma

Huang,

Zhang,

Yang

et al. 2024

BMC Genomics

View full text Add to dashboard Cite

Background DNA damage repair (DDR) may affect tumorigenesis and therapeutic response in hepatocellular carcinoma (HCC). Long noncoding RNAs (LncRNAs) can regulate DDR and play a vital role in maintaining genomic stability in cancers. Here, we identified a DDR-related prognostic signature in HCC and explored its potential clinical value. Methods Data of HCC samples were obtained from the Cancer Genome Atlas (TCGA), and a list of DDR-related genes was extracted from the Molecular Signatures database (MSigDB). A DDR-related lncRNAs signature associated to overall survival (OS) was constructed using the least absolute shrinkage and selection operator-cox regression, and was further validated by the Kaplan-Meier curve and receiver operating characteristic curve. A nomogram integrating other clinical risk factors was established. Moreover, the relationships between the signature with somatic mutation, immune landscape and drug sensitivity were explored. Results The prognostic model of 5 DDR-related lncRNAs was constructed and classified patients into two risk groups at median cut-off. The low-risk group had a better OS, and the signature was an independent prognostic indicator in HCC. A nomogram of the signature combined with TNM stage was constructed. TP53 gene was more frequently mutated in the high-risk group. Marked differences in immune cells were observed, such as CD4 + T cells, NK cells and macrophages, between the two groups. Moreover, an increase in the expression of immune checkpoint molecules was found in the high-risk group. The low-risk group presented with a significantly higher response to sorafenib or cisplatin. Finally, potential value of this signature was validated in real-world HCC patients. Conclusion Our findings provided a promising insight into DDR-related lncRNAs in HCC and a personalized prediction tool for prognosis and therapeutic response.

show abstract

“…Liver cancer is one of the most common malignant tumors of digestive system in the world.According to the global cancer data released in 2020,Liver cancer accounts for 4.6% of all new cancers in the world, and its deaths account for 8.3% of all cancer deaths, which is the sixth largest cause of cancer incidence and the third largest cause of cancer death in the world [1]. Because of the large population base, 50% of the world's new liver cancer cases and deaths are all in China.The main risk factors of liver cancer include chronic infection caused by hepatitis B virus (HBV) or hepatitis C virus (HCV), eating food contaminated with a atoxin and drinking heavily etc [2][3]. 85% − 90% of liver cancer are hepatocellular carcinoma(HCC) [4].…”

Section: Introductionmentioning

confidence: 99%

A Novel Differentially Expressed Cuproptosis-Related lncRNAs Signature to predict the prognosis and immune characteristics of hepatocellular carcinoma

Yin

Gao

Sun

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: According to a growing body of research, long non-coding RNAs (lncRNAs) participate in the progress of hepatocellular carcinoma (HCC). Cuproptosis is a distinct kind of programmed cell death, separating it from several other forms of programmed cell death that may be caused by genetic programming. Consequently, our aim was to investigate the relationship between Differentially Expressed Cuproptosis-Related lncRNAs (DECRLs) and clinical outcome and immune characteristics of HCC. Method: The Cancer Genome Atlas (TCGA) database was used to retrieve related data. The GSE101728 dataset was downloaded from the Gene Expression Omnibus (GEO) database. A list of cuproptosis-related genes (CRGs) was obtained from a recently published article in Science. Combined analysis of TCGA dataset and the GSE101728 dataset identified differentially expressed CRGs(DECRGs).We can obtain DECRLs via co-expression. Then, using DECRLs, we developed a risk prediction model using Cox regression analysis and the least absolute shrinkage selection operator (LASSO) regression analysis. To evaluate the diagnostic accuracy of this model, a Kaplan-Meier (K-M) survival analysis and a receiver operating characteristic (ROC) curve analysis were used. Next, principal component analysis (PCA) was carried out.Moreover, the relationships between the risk model and immune characteristics, somatic mutation, and drug sensitivity were also investigated. Finally Real-Time quantitative PCR(RT-qPCR) and Western Blot confirmed the expression of DECRGs or DECRLs in HCC. Results: Three high-risk DECRLs(AL031985.3,AC107959.3,MKLN1-AS) that can guide HCC prognosis and immune microenvironment were obtained through cox regression analysis.Immune functions such as APC co-inhibition,Type-II-IFN-Reponse,Parainflammation,MHC-class-I, and Tumor Immune Dysfunction and Exclusion(TIDE) score, and Tumor Mutation Burden(TMB) were significantly different in high-risk and low-risk groups.Moreover, this research also found that the IC50 values for 87 chemotherapeutic drugs varied widely across patients within high and low-risk groups.The expression of GLS at both mRNA and protein levels was significantly raised in HCC,and that of CDKN2A was dropped in HCC. The mRNA expression level of AL031985.3,AC107959.3 and MKLN1-AS was upregulated in HCC. Conclusion: The proposed 3-DECRLs that can predict clinical prognosis or guide the immune characteristics and drugs that may have a potential curative effect on HCC received in our research may play a major role in patient management and immunotherapy.

show abstract

The roles of lncRNA functions and regulatory mechanisms in the diagnosis and treatment of hepatocellular carcinoma

Cited by 5 publications

References 199 publications

Hallmarks of cancer resistance

Hallmarks of cancer resistance

Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma

A Novel Differentially Expressed Cuproptosis-Related lncRNAs Signature to predict the prognosis and immune characteristics of hepatocellular carcinoma

Contact Info

Product

Resources

About